Max Robotics — Global Service Robot Directory + US Certification

About

Thomas Jiborn is a leading urologic surgeon and researcher whose work has fundamentally shaped the understanding of functional outcomes and surgical safety in prostate cancer treatment. His primary research focuses on the preservation of urinary continence following radical prostatectomy and the prevention of thromboembolic complications in surgical patients. Jiborn’s landmark 2014 study, cited over 160 times, demonstrated a direct correlation between the degree of neurovascular bundle preservation during radical prostatectomy and urinary continence one year after surgery—a finding that has influenced surgical technique worldwide. His earlier multi-institutional work on venous thromboembolism, with 146 citations, established critical benchmarks for perioperative risk in laparoscopic and robot-assisted prostatectomy. Jiborn also contributed to methodological rigor in prostate cancer research through his investigation of interobserver variability in pathological assessment of prostatectomy specimens, a key component of the influential LAPPRO study. More recently, he has explored the accuracy of [18F]-fluorocholine PET/CT for lymph node staging in intermediate and high-risk patients, contributing to the evolving landscape of precision imaging. Across his career, Jiborn’s work has consistently bridged surgical technique, patient quality of life, and evidence-based practice.